| Date | Title | Description |
| 16.01.2024 | Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments | Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial
Source: Prota Therapeutics
Sectors: BioTech |
| 16.01.2024 | Stalicla Secures $17.4 Million in Series B Financing | - |
| 02.11.2023 | RegASK Welcomes New Chief Product & Technology Officer | NEW YORK and SINGAPORE, Nov. 2, 2023 — RegASK, a global regtech SaaS platform that enables businesses to leverage AI to scale their regulatory and compliance capabilities, announces the appointment of Amenallah (Amen) Reghimi as its new Chi... |
| 17.10.2023 | ObvioHealth Strengthens Leadership Team with Key Industry Appointments | - |
| 10.10.2023 | Fibronostics Announces Partnership with Stone Diagnostics | - |
| 29.09.2023 | Spexis provides business update and announces financial results for the first half of 2023 | Ad hoc announcement pursuant to Art. 53 LR
ALLSCHWIL, Switzerland, Sept. 28, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today... |
| 14.08.2023 | Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies | ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capital commitment totaling USD ... |
| 14.07.2023 | Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight | - |
| 26.05.2023 | SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd. | - |
| 03.05.2023 | ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers | - |
| 18.04.2023 | Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study | Ad hoc announcement pursuant to Art. 53 LR
ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company ... |
| 06.04.2023 | AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates | AUM Biosciences, a Singapore-headquartered biotech company focused on precision oncology therapeutics, allotted shares worth $11.8 million earlier this week.
Everlife Holdings, a market access and distribution company in India and Southeas... |
| 28.03.2023 | 1nHealth Launches Site Advisory Board to Prioritize Site Voice | ORLANDO, Fla., March 28, 2023 (Newswire.com) – Today, 1nHealth launched its Site Advisory Board, a consortium of research site owner-operators brought together to advise 1nHealth’s recruitment efforts and technology development. The board w... |
| 27.03.2023 | STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD | STALICLA and Firefly Neuroscience enterPartnership Agreement for the Development of Electroencephalogram (EEG) asa Biomarker for Subgroups of Patients with ASD
Geneva, Switzerland – 27March2023, STALICLA S.A. and Firefly Neuroscience today... |
| 16.03.2023 | ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine | NEW YORK, March 16, 2023 /PRNewswire/ — ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines. The randomized controlled tri... |
| 09.02.2023 | Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A. | This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million
Jaguar currently owns approximately 73.5% of Napo Therape... |
| 08.02.2023 | Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin® | ALLSCHWIL, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company has executed term sheets describing a clinica... |
| 09.01.2023 | STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment | PRESS RELEASE
Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, today announced that it has entered into ... |
| 15.12.2022 | RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth | SINGAPORE, Dec. 15, 2022 /PRNewswire/ — RegASK, a global RegTech SaaS company, today announced it has raised a $10m Series A funding round. The round is led by venture capital firm Monograph Capital and joined by SPRIM Global Investments an... |
| 20.10.2022 | AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V | SINGAPORE and NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer... |
| 12.10.2022 | Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01 | - |
| 18.08.2022 | AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene | SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) — AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Admin... |
| 16.08.2022 | ObvioHealth Ranked on Inc. 5000’s List of Fastest Growing Private Companies for Second Consecutive Year | NEW YORK, Aug. 16, 2022 /PRNewswire/ — ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces today its inclusion in Inc. Magazine’s annual list of the natio... |
| 27.06.2022 | Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer | LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient ... |
| 15.06.2022 | Fibronostics Secures Financing, Announces New CEO | NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichw... |
| 02.04.2022 | LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients. |
This final part of the video informative series focuses on LIVERFASt, a non-invasive AI driven technology that helps provide quantitative assessments of lesions (fibrosis, steatosis, inflammatory activity).
Dr Mona Munteanu, the Fibronos... |
| 05.03.2022 | Faster, safer, more accurate trials. | ObvioHealth is pioneering new ways to collect clinical trial data. Their innovative platform seamlessly integrates with clinical-grade devices, their novel instruments reduce ePRO subjectivity, and their virtual study coordinators carefully... |
| 08.02.2022 | SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy | SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to the business, boost... |
| 08.12.2021 | The Digital Health 150: The Top Digital Health Companies Of 2021 | CB Insights has unveiled the third annual Digital Health 150 — a list of 150 of the top private companies using digital technology to transform healthcare.
The 2021 Digital Health 150 cohort has raised approximately $14.9B in aggregate fun... |
| 16.11.2021 | GHO Capital Acquires Genesis Research, a Pioneer in Tech-enabled Real-World Evidence and HEOR Services | - |
| 12.10.2021 | AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies | SINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging w... |
| 14.09.2021 | ObjectiveGI Announces Name Change to ObjectiveHealth | - |
| 01.07.2021 | ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally |
NEW YORK –July 1, 2021 – ObvioHealth, a global Virtual Research Organization(VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT ... |
| 07.06.2021 | ObvioHealth Announces a Groundbreaking Partnership with Dedalus Group to Unite Real World & Clinical Trial Data |
NEW YORK – June 7, 2021 – ObvioHealth, a global virtual research organization (VRO), is bringing clinical trial data fully into the continuum of care through a new strategic partnership with Dedalus Group, the leading healthcare and dia... |
| 01.03.2021 | Leveraging Next-Gen Tools in Rare Disease Research | The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are over 6,000 rare diseases global... |
| 07.01.2021 | Genesis Research Announces Acquisition of Evid Science | HOBOKEN, N.J. (PRWEB) JANUARY 07, 2021
Genesis Research LLC (GR), a Value Demonstration Company providing Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services to the health and life sciences industries, anno... |
| 24.08.2020 | Fibronostics Raises $8 Million in Series A Financing | - |
| 05.08.2020 | Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors | - |
| 23.06.2020 | The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training | The FDA recently released new guidance on drug development for the prevention and treatment of COVID-19, emphasizing the need for flexible trial designs, diverse patient populations and mechanisms to ensure data accuracy.
Digital component... |
| 18.06.2020 | ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients | - |
| 11.06.2020 | Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million | - |
| 08.06.2020 | SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD | - |
| 20.05.2020 | ObvioHealth Secures $17 Million in Latest Investment Round | - |
| 12.05.2020 | Travecta Therapeutics Secures $15 Million in Financing | - |
| 10.02.2020 | Ventures Day Singapore 2020: Post-event highlights | Following our three successful past events – June 2017 & January 2019 in Singapore and April 2019 in New York – SPRIM held another exciting Ventures Day at our brand new auditorium in Singapore.
Our CEOs, science/tech experts, and stra... |
| 07.06.2019 | AC Health Announces Investment in Fibronostics | Ayala Healthcare Holdings, through its technology arm, Vigos, expanded its digital portfolio with a recent investment in SPRIM’s sister company, Fibronostics. The agreement was signed by AC Health President and CEO, Paolo Borromeo, AC Healt... |
| 21.03.2019 | SPRIM’s Quarterly Ventures Day Meeting in New York | SPRIM, in partnership with Tikehau Capital, is hosting its quarterly Ventures Day meeting on April 24, and for the first time, the event will take place in New York.
This one-day meeting will provide unique insights into trends in biotech ... |
| 29.01.2019 | Objective GI Funding Announcement |
The clinical research company establishes partnerships with gastroenterology practices and is forecasted to grow to more than 30 research sites across the U.S.
NASHVILLE, Tenn. – January 29, 2019 – Objective GI, a gastrointestinal-focuse... |
| 28.01.2019 | TKS 1 Investor Day 2019 in Singapore: Post Event Highlights | Following a successful Ventures Day in 2017, we are back with yet another great event organized in collaboration with Tikehau Capital. This year’s event was held on Friday, January 25, 2019, at the Four Seasons Hotel in Singapore where we w... |
| 15.01.2019 | RegASK, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth | RegAsk uses artificial intelligence to answer regulatory questions, including inquiries about path-to-market, path-to-claim, product registration and regulatory strategy
SINGAPORE, January 15, 2019 – RegAsk, a company that uses artificial ... |
| 15.11.2018 | SPRIM and Tikehau Capital Join Forces with New Singapore-based Life Sciences VC Fund | LIFE science startups hoping for a big break can now look to a new Singapore-based cash cow for funding.European asset manager Tikehau Capital and Sprim Ventures, the venture arm of global healthcare consultancy Sprim, have teamed up to lau... |
| 15.11.2018 | Evid Science Receives Seed Capital to Advance Clinical AI Platform | LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early-stage life science c... |
| 23.03.2018 | ObvioHealth Raises $3 Million in Series A Funding | OBVIOHEALTH, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding.
The financing round, led by TKS I, a life science and healthcare focused ven... |
